OUTCOMES OF BLINATUMOMAB THE INITIAL PHASE OF CHEMOTHERAPY IN CHILDREN WITH B-CELL ALL

IBRAGIMOVA Sapura, KLEVLEEVA Albina, BABAKHANOVA Nargiza, RIZAYEVA Feruza, ERIMBETOVA Indira, NIGMATOV Khamidhon, ARIPOVA Nazokat

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali · 2025-yil

Annotatsiya

This retrospective single‑center study (2020–2024) from the Pediatric Oncology Center in Tashkent evaluated the efficacy of incorporating blinatumomab (14‑day courses at 15 μg/m²/day, twice with a two‑month interval) into the ALL‑MB‑2015 protocol for children with B‑cell ALL who remained MRD‑positive post‑induction. All 25 patients achieved hematologic remission; MRD dropped from 12 % to 0.001 % after the first blinatumomab course, and remained negative after the second. Median follow‑up was 2.5 years. There were two late relapses (in standard‑ and intermediate‑risk groups), 4‑year EFS was 88.1 ± 3.7 %, and no deaths occurred. Adverse events (allergic reactions, neurotoxicity, hypoalbuminemia, cytopenias) were manageable.

Maqola ma’lumotlari
MualliflarIBRAGIMOVA Sapura, KLEVLEEVA Albina, BABAKHANOVA Nargiza, RIZAYEVA Feruza, ERIMBETOVA Indira, NIGMATOV Khamidhon, ARIPOVA Nazokat
JurnalJournal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali
Nashr sanasi2025-11-21
Jild10
Son5
TilIngliz

Kalit so‘zlar

острая лимфобластная лейкемия (ALL), блинатумомаб, минимальная остаточная болезнь (MRD), дети, протокол ALL MB 2015, ALL, blinatumomab, minimal residual disease, children, B-hujayrali OLL, blinatumomab, minimal qoldiq kasallik (MRD), bolalar, immunoterapiya

Ilmiy soha

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali jurnalidan boshqa maqolalar

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali — barcha maqolalar